
Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: A phase IV, randomized, open-label, controlled study
Keywords: AS03; H5N1 vaccine; Pandemic influenza; Korean adults; AEs; adverse events; CBER; US Center for Biologics Evaluation and Research; CHMP; Committee for Medicinal Products for Human Use; CI; confidence interval; EMA; European Medicines Agency; FDA; US Food